11th AIS 2023
Join us in-person in Tours, France for the Antibody Industrial Symposium where Just – Evotec Biologics will be presenting our science.
- Nigel Shipston, Senior Director Business Development at Just – Evotec Biologics
Leveraging Continuous Manufacturing to de-risk development from IND filing through to market supply
Just-Evotec Biologics has developed a continuous bioprocessing platform based on intensified perfusion cell culture and connected downstream processing for the manufacturing of monoclonal antibodies (mAbs) and related molecules such as bispecific antibodies and Fc fusion proteins. The platform has been established at 500L / 1000L bioreactor scale in a relatively small footprint cGMP manufacturing facility (J.POD) and is now being used to routinely manufacture bulk drug substance for clinical supply. This presentation will outline some of the key advantages of this strategy for the manufacturing of clinical and commercial material and describe how it can be used in conjunction with AI/ML based molecular optimization to improve manufacturability, reduce cost of goods (COGS) and offer truly flexible capacity (from few kilograms to metric tons of DS with the same process and scale). An update on our global expansion plan with a focus on our biologics manufacturing facility in Toulouse, France (J.POD2) will also be provided.
Presented by Nigel Shipston, Senior Director Business Development at Just – Evotec Biologics
Nigel ShipstonSenior Director, Business Development
Nigel is responsible for Biologics Business Development activities in the UK and Europe. Prior to joining Evotec in 2021, Nigel spent 14 years at FUJIFILM Diosynth Biotechnologies as Director of Technical Marketing, Director of Program Design and Senior Technical Project Leader, supporting expansion of the business in Europe, USA and APAC. and has also served as Head of Process Development at Angel Biotechnology and has previously held Operations Manager and Senior Scientist positions at Oxford GlycoSciences and Abbott Laboratories. He has 30 years’ experience in the biotechnology industry and has been responsible for leading process development and manufacturing teams involved in the expression, purification and analysis of many commercially relevant recombinant protein biopharmaceuticals (biologics) and enzyme products.
Nigel received his BSc and Associateship of the Royal College of Science degrees from Imperial College of Science and Technology, London, UK and a PhD in biochemistry from the University of Kent, UK.